Thermedical develops the Saline Enhanced Radiofrequency (SERF) Ablation System and the Durablate catheter to treat ventricular tachycardia (VT) and other ventricular arrhythmias. The company’s SERF approach provides a different form of biological heat transfer intended to reach tissue deeper in the heart wall than conventional radiofrequency ablation. Thermedical is privately held, founded by MIT Hyperthermia Center alumni Michael G. Curley, Ph.D., and Patrick S. Hamilton, Ph.D., and is based in Waltham, Mass. It has received prior support including a Massachusetts Life Sciences Center Small Business Matching Grant, multiple NIH SBIR grants, and Series A venture funding. The company reports strong early clinical results: in a recent multi-center trial 38 of 41 participants experienced immediate elimination of their clinical VT at the end of the procedure, and shock or pacing therapies were substantially reduced or eliminated in 73% of those patients at six months. Thermedical plans to use current funding to support an FDA-approved clinical trial at seven centers in the U.S. and Canada and will showcase the SERF system at an international VT symposium. Thermedical develops thermal-ablation systems to treat cancer and cardiac arrhythmias. The company was founded by MIT Hyperthermia Center alumni Michael G. Curley, Ph.D. and Patrick S. Hamilton, Ph.D. It received FDA clearance in October 2012 for its technology for coagulation and ablation of soft tissue during percutaneous, laparoscopic, and intraoperative surgical procedures. Thermedical intends to use recent financing to hire technical staff and continue research into ablation of solid tumors and ventricular tachycardia. The company plans to begin first-in-man studies later this year. It is based in Waltham, Massachusetts. Thermedical is a Somerville, Mass.–based privately held company developing proprietary thermal therapy and ablation equipment, including preclinical prototypes of a Saline-Enhanced Radio Frequency (SERF™) ablation system. The SERF system targets malignant solid tissue such as liver cancer and difficult-to-treat cardiac arrhythmias like ventricular tachycardia (VT). Thermedical was founded by Michael G. Curley, Ph.D., and Patrick S. Hamilton, Ph.D., and has received multiple NIH Small Business Innovation Research (SBIR) grants and a Massachusetts Life Sciences Center Small Business Matching Grant. The company says the ablation therapy is designed to increase survival and improve quality of life for liver cancer patients and potentially cure VT. Thermedical recently closed a $1.5 million Series A financing from private investor Samuel H. Maslak, Sc.D., to fund continued research and development and additional patent filings. Proceeds will also support efforts to achieve 510(k) regulatory clearance from the U.S. Food and Drug Administration.

Total raised

$10M

Funding rounds

3

Latest round

Grant

Latest activity

Oct 2023